Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2018. Oral Presentation
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML. ASH 2018.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML. ASH 2018. Poster
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2018. Poster
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival. ASCO 2018. Poster
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. EHA 2018. Oral Presentation
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. EHA 2018. Poster
Results from Ongoing Phase ½ Trial of SL-401 in Patients with Relapsed/Refractory CMML. EHA 2018.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML. EHA 2018. Poster
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), Kills Plasmacytoid Dendritic Cells (pDCs) from Systemic Sclerosis Patients
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), Kills Plasmacytoid Dendritic Cells (pDCs) from Systemic Sclerosis Patients. EULAR 2018. Poster
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors.
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors. ASCO 2018. Poster
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM. SNO 2017. Oral Presentation